Suspension of trading
Valuation Eiger BioPharmaceuticals
Stocks
EIGR
US28249U2042
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.500 USD | -.--% |
|
-.--% | - |
| 24-10-01 | Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect | CI |
| 24-09-30 | Eiger BioPharmaceuticals, Inc. Went Out of Business | CI |
Company Valuation: Eiger BioPharmaceuticals
Data adjusted to current consolidation scope
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 194 | 365 | 399.8 | 176.3 | 52.01 | 9.964 |
| Change | - | 88.12% | 9.55% | -55.9% | -70.51% | -80.84% |
| Enterprise Value (EV) 1 | 119.3 | 302.2 | 303.5 | 120.1 | -11.28 | 25.32 |
| Change | - | 153.38% | 0.42% | -60.44% | -109.4% | 324.43% |
| P/E | -2.66x | -4.83x | -5.32x | -5.19x | -0.51x | -0.13x |
| PBR | 2.93x | 6.47x | 4.38x | 2.48x | 0.94x | -0.69x |
| PEG | - | 0.3x | 0.2x | 0.1x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 14,522,675x | 3,856,989x | 631,735x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.34x | -4.39x | -4.9x | -1.57x | 0.12x | -0.35x |
| EV / EBIT | -2.34x | -4.39x | -4.88x | -1.56x | 0.12x | -0.35x |
| EV / FCF | -4.96x | -8.22x | -7.89x | -2.89x | 0.23x | -0.48x |
| FCF Yield | -20.2% | -12.2% | -12.7% | -34.6% | 426% | -210% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -114.6 | -92.5 | -69.34 | -29.98 | -69.74 | -50.78 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | 12.14 | 13.48 | 15.77 |
| EBITDA 1 | -50.99 | -68.84 | -61.98 | -76.66 | -92.45 | -71.51 |
| EBIT 1 | -51.05 | -68.9 | -62.15 | -76.94 | -92.74 | -71.79 |
| Net income 1 | -52.39 | -70.25 | -65.05 | -33.92 | -96.78 | -74.96 |
| Net Debt 1 | -74.73 | -62.75 | -96.33 | -56.28 | -63.29 | 15.36 |
| Reference price 2 | 304.800 | 447.000 | 368.700 | 155.700 | 35.400 | 6.735 |
| Nbr of stocks (in thousands) | 637 | 817 | 1,084 | 1,133 | 1,469 | 1,479 |
| Announcement Date | 3/14/19 | 3/13/20 | 3/9/21 | 3/10/22 | 3/17/23 | 4/8/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 12.59M | |
| 34.06x | 5.97x | 18.46x | 0.97% | 48.5B | |
| -22.99x | 334.06x | -20.92x | -.--% | 38.97B | |
| 48.09x | 4.84x | 31.06x | -.--% | 35.43B | |
| 24.54x | 2.74x | 11.83x | -.--% | 33.65B | |
| 26.5x | 7.78x | 19.53x | 0.43% | 26.58B | |
| 31.4x | 5.06x | 23.02x | -.--% | 15.18B | |
| 23.86x | 2.05x | 9.01x | 1.1% | 13.89B | |
| 23.55x | 1.88x | 11.39x | -.--% | 12.76B | |
| Average | 23.62x | 45.55x | 12.92x | 0.31% | 25B | |
| Weighted average by Cap. | 22.66x | 61.82x | 12.08x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EIGR Stock
- Valuation Eiger BioPharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
